Version history

{
  "session_id": "sess_SDA-2026-04-15-gap-debate-20260410-112330-9abf86eb_20260415-165431",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "support",
  "content": "\n\n# Domain Expert Assessment: Astrocytic Ketone Therapeutic Window\n\n---\n\n## 1. Hypotheses with Highest Translational Potential\n\n### Rank 1: SIRT3-Mediated Neuronal Mitochondrial Resilience (Hypothesis 2)\n**Rationale:** This hypothesis offers the strongest alignment with current AD drug development infrastructure. SIRT3 activators (NAD+ precursors, SIRT3-selective small molecules) are in early clinical pipelines for metabolic diseases, creating a potential fast-track for neurological indications. Critically, this mechanism explains *why* neurons remain capable of ketone oxidation—the therapeutic window's defining criterion—rather than attributing it to an unexplained residual capacity.\n\n### Rank 2: Integrated Ketogenic Capacity Index (Composite Hypothesis)\n**Rationale:** Neither single mechanism (production nor transport) is sufficient. A composite metric integrating astrocytic HMG-CoS II activity, circulating ketone levels, and neuronal BDH1 expression would better operationalize the therapeutic window for clinical trial enrollment. This approach is already being piloted in ketogenic diet trials for epilepsy using composite metabolic biomarkers.\n\n### Rank 3: Astrocytic MCT1/MCT2 Transport (Hypothesis 1, with modification)\n**Rationale:** Despite the skeptic's valid critique, MCT1 remains clinically relevant because exogenous ketone esters (currently in Phase II for AD; NCT04652734) must still cross the BBB. Understanding transport kinetics informs dosing and patient stratification even if MCT1 isn't the rate-limiting *production* defect.\n\n---\n\n## 2. Clinical Evidence, Safety, and Patient Population Fit\n\n### SIRT3 Hypothesis\n\n| Dimension | Assessment |\n|-----------|------------|\n| **Current Clinical Evidence** | Moderate. NAD+ precursor trials (nicotinamide riboside, NCT03094573) show safety in older adults. SIRT3 expression is reduced in AD postmortem tissue (PMID: 31829346), but no direct SIRT3 activator has entered AD trials. |\n| **Safety Considerations** | NAD+ precursors have favorable safety profiles. SIRT3 overexpression in cancer models raises theoretical concerns about metabolic reprogramming, though brain-specific effects remain poorly characterized. |\n| **Patient Population Fit** | Ideal for early-stage AD (prodromal MCI) where mitochondrial resilience mechanisms are most intact. Less suited for advanced AD where neuronal loss may be irreversible. Syntactically aligns with ongoing trials targeting metabolic dysfunction in Type 2 diabetes with AD comorbidity. |\n\n### Modified MCT1 Hypothesis\n\n| Dimension | Assessment |\n|-----------|------------|\n| **Current Clinical Evidence** | Ketone ester trials (BetaHydroxyButyrate, AC-1202) show modest cognitive benefits in mild-moderate AD (NCT01255111). MCT1 expression correlates with cerebral glucose metabolism on FDG-PET. |\n| **Safety Considerations** | Exogenous ketone esters carry GI tolerability issues (dose-dependent nausea, diarrhea). MCT1 modulators have not been tested in CNS; systemic MCT1 inhibition causes hematologic toxicity. |\n| **Patient Population Fit** | Best for patients with confirmed hypometabolism on FDG-PET who are not on ketogenic diets. Stratification by APOE4 status is critical—APOE4 carriers show blunted ketogenesis during ketogenic diets (PMID: 32182118). |\n\n---\n\n## 3. Response to Skeptic's Most Important Challenge\n\nThe Skeptic's strongest critique of Hypothesis 1 is the **conflation of production vs. export**, which fundamentally weakens the mechanistic model. I concede this point but argue it does not eliminate MCT1 from therapeutic consideration—it refines its role.\n\n**My position:** The therapeutic window is not defined by a single step but by a **rate-limiting coordinate** that shifts across disease progression:\n\n1. **Early AD (prodromal):** Astrocytic ketone *production* is rate-limiting. HMG-CoS II activity and substrate availability (cysteine via system xc-) determine window boundaries.\n2. **Moderate AD:** Export becomes rate-limiting as MCT1 expression declines on astrocytes, even if production capacity remains partially intact.\n3. **Advanced AD:** Neuronal oxidation capacity becomes the constraint; SIRT3-mediated resilience becomes the final gatekeeper.\n\n**Evidence for this coordinate model:** Postmortem studies in AD brain show progressive loss of astrocytic HMG-CoS II (PMID: 25943887) followed by reduced neuronal MCT2 and mitochondrial complex I dysfunction. The therapeutic window exists where intervention on",
  "tokens_used": "1119"
}